Literature DB >> 27005528

[Disease burden of liver cancer in Jinchang cohort].

Xiaobin Hu1, Yana Bai1, Hongquan Pu2, Kai Zhang3, Ning Cheng4, Haiyan Li2, Xiping Shen1, Fuxiu Li2, Xiaowei Ren1, Jinbing Zhu2, Shan Zheng1, Minzhen Wang1, Min Dai3.   

Abstract

OBJECTIVE: To understand the current status of the disease burden of liver cancer in Jinchang cohort.
METHODS: All the liver cancer death data from 2001 to 2013 and medical records of liver cancer cases from 2001 to 2010 in Jinchang cohort were collected for the analyses of the mortality, standardized mortality, potential years of life lost (PYLL) and working PYLL (WPYLL) associated with liver cancer. Spearman correlation and the average growth rate were used to analyze the trends.
RESULTS: A total of 207 liver cancer deaths occurred in Jinchang cohort from 2001 to 2013, accounting for 16.68% of total cancer deaths. There were 259 liver cancer inpatients, accounting for 6.79% of the total cancer cases inpatients, in which 83 died (32.05%). Liver cancer death mainly occurred in males, accounting for 88.89%, and the liver cancer deaths in females accounted for 11.11%. The standardized mortality rate was 42.32/100,000 in males and 15.31/100,000 in females. The growth rate of liver cancer mortality was 5.62% from 2001 to 2013. Liver cancer deaths mainly occurred in age groups 60-69 years (26.57%) and 50-59 years (24.15%). The PYLL was 2906.76 person-years, the average PYLL was 14.04 years. The WPYLL was 1477.00 person-years and the average WPYLL was 7.14 years. The direct economic burden of liver cancer was 6270.78 Yuan per person, 301.75 Yuan per day. The average stay of hospitalization was 21.32 days.
CONCLUSION: The mortality rate of liver cancer is increasing and the disease burden is still heavy.

Entities:  

Mesh:

Year:  2016        PMID: 27005528     DOI: 10.3760/cma.j.issn.0254-6450.2016.03.005

Source DB:  PubMed          Journal:  Zhonghua Liu Xing Bing Xue Za Zhi        ISSN: 0254-6450


  1 in total

1.  No expenditure difference among patients with liver cancer at stage I-IV: Findings from a multicenter cross-sectional study in China.

Authors:  Haike Lei; Lin Lei; Jufang Shi; Yongzhong Wu; Ling Liang; Huiyao Huang; Mei He; Fangzhou Bai; Maomao Cao; Hui Qiu; Yuting Wang; Chengcheng Liu; Jia Du; Hong Wang; Yan Zhang; Mengdi Cao; Ji Peng; Ni Li; Chunfeng Qu; Min Dai; Wanqing Chen; Jie He
Journal:  Chin J Cancer Res       Date:  2020-08       Impact factor: 4.026

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.